Rupatadine improves nasal symptoms, airflow and inflammation in patients with persistent allergic rhinitis: A pilot study

Journal of Biological Regulators and Homeostatic Agents

Volumn 24, Issue 2, 2010, Pages 177-183

  Ciprandi, Giorgio ^a   Cirillo, I ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b Navy Medical Service   (Italy)

Author keywords

Nasal airflow; Nasal mediators; Nasal obstruction; Ocular symptoms; Persistent allergic rhinitis; Rupatadine

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; RUPATADINE; TRYPTASE; ANTIALLERGIC AGENT; CYPROHEPTADINE; DRUG DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NOSE AIRFLOW; NOSE OBSTRUCTION; PERENNIAL RHINITIS; PILOT STUDY; RHINOMANOMETRY; TREATMENT DURATION; TREATMENT OUTCOME; ANAMNESIS; DRUG ANTAGONISM; HAY FEVER; PATHOPHYSIOLOGY; PATIENT SELECTION;

ADULT; ANTI-ALLERGIC AGENTS; CYPROHEPTADINE; FEMALE; HUMANS; INFLAMMATION; MALE; MEDICAL HISTORY TAKING; PATIENT SELECTION; PILOT PROJECTS; PLATELET ACTIVATING FACTOR; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 77955872490     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Horak F. Impact and modulation of nasal obstruction. Allergy 2002; 57:25-28.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008; 63(S):8-160.
3. Bousquet J. Requirements for medication commonly used in the treatment of allergic rhinitis. Allergy 2003; 58:192-7.
4. Gentile DA, Friday GA, Skoner DP. Management of allergic rhinitis: antihistamines and decongestants. Immunol Clin North Am 2000; 20:355-68.
5. Horak F, Stubner UP, Ziegelmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109:956-61.
6. Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW. Fexofenadine treatment reduces nasal congestion in allergic rhinitis Allergy 2001; 56:1068-70.
7. Ciprandi G, Cirillo I, Mora F, La Rosa M. Ebastine improves nasal symptoms and airflow and affects response to decongestion test in patients with persistent allergic rhinitis: a pilot study. Allergy Asthma Proc 2007; 28:578-81.
8. Mullol J, Bousquet J, Bachert C, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy 2008; 63(S):5-28.
9. Fantin S, Maspero J, Bisbal C, Agache I, Donado E, Borja J, Mola O, Izquierdo I. A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy 2008; 63:924-31.
10. Ciprandi G, Cirillo I, Vizzaccaro A, Milanese M, Tosca MA. Nasal obstruction in patients with seasonal allergic rhinitis: relationships between allergic inflammation and nasal airflow. Int Arch Allergy Immunol 2004; 134:34-40. (Pubitemid 38698097)
11. Tsicopoulos M, de Nadai P. Anti-histamines as anti-inflammatory agents. Clin Exp Allergy 2003; 33: 1476-8.
12. Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and PAF. J Pharmacol Exp Ther 1997; 280:114-21.
13. Vasiadi M, Kalogeromitros D, Kempuraj D, et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol 2010; 15:38-45.
14. Barron S, Ramis I, Garcia-Rafanell J, Merlos M. Inhibitory activity of rupatadine on pro-inflammatory cytokine production, relationship with binding affinity. Methods Find Exp Clin Pharmacol 2005; 27(S):161-2.
15. Valero A, Serrano C, Bartrá J, Izquierdo I, Muñoz-Cano R, Mullol J, Picado C. Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study. J Investig Allergol Clin Immunol 2009; 19:488-93.
16. Valero A, de la Torre F, Castillo JA, Rivas P, del Cuvillo A, Antépara I. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre open-label study in Spain. Drug Saf 2009; 32:33-42.